51 related articles for article (PubMed ID: 22749643)
1. Synthesis and biological evaluation of 3-benzisoxazolyl-4-indolylmaleimides as potent, selective inhibitors of glycogen synthase kinase-3β.
Ye Q; Li M; Zhou Y; Pang T; Xu L; Cao J; Han L; Li Y; Wang W; Gao J; Li J
Molecules; 2013 May; 18(5):5498-516. PubMed ID: 23669633
[TBL] [Abstract][Full Text] [Related]
2. The marine natural-derived inhibitors of glycogen synthase kinase-3beta phenylmethylene hydantoins: In vitro and in vivo activities and pharmacophore modeling.
Khanfar MA; Asal BA; Mudit M; Kaddoumi A; El Sayed KA
Bioorg Med Chem; 2009 Aug; 17(16):6032-9. PubMed ID: 19616957
[TBL] [Abstract][Full Text] [Related]
3. Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for Alzheimer's disease.
Hamann M; Alonso D; Martín-Aparicio E; Fuertes A; Pérez-Puerto MJ; Castro A; Morales S; Navarro ML; Del Monte-Millán M; Medina M; Pennaka H; Balaiah A; Peng J; Cook J; Wahyuono S; Martínez A
J Nat Prod; 2007 Sep; 70(9):1397-405. PubMed ID: 17708655
[TBL] [Abstract][Full Text] [Related]
4. Structural Basis for Achieving GSK-3β Inhibition with High Potency, Selectivity, and Brain Exposure for Positron Emission Tomography Imaging and Drug Discovery.
Bernard-Gauthier V; Mossine AV; Knight A; Patnaik D; Zhao WN; Cheng C; Krishnan HS; Xuan LL; Chindavong PS; Reis SA; Chen JM; Shao X; Stauff J; Arteaga J; Sherman P; Salem N; Bonsall D; Amaral B; Varlow C; Wells L; Martarello L; Patel S; Liang SH; Kurumbail RG; Haggarty SJ; Scott PJH; Vasdev N
J Med Chem; 2019 Nov; 62(21):9600-9617. PubMed ID: 31535859
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a Highly Selective Glycogen Synthase Kinase-3 Inhibitor (PF-04802367) That Modulates Tau Phosphorylation in the Brain: Translation for PET Neuroimaging.
Liang SH; Chen JM; Normandin MD; Chang JS; Chang GC; Taylor CK; Trapa P; Plummer MS; Para KS; Conn EL; Lopresti-Morrow L; Lanyon LF; Cook JM; Richter KE; Nolan CE; Schachter JB; Janat F; Che Y; Shanmugasundaram V; Lefker BA; Enerson BE; Livni E; Wang L; Guehl NJ; Patnaik D; Wagner FF; Perlis R; Holson EB; Haggarty SJ; El Fakhri G; Kurumbail RG; Vasdev N
Angew Chem Int Ed Engl; 2016 Aug; 55(33):9601-5. PubMed ID: 27355874
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of [(11)C]PyrATP-1, a novel radiotracer for PET imaging of glycogen synthase kinase-3β (GSK-3β).
Cole EL; Shao X; Sherman P; Quesada C; Fawaz MV; Desmond TJ; Scott PJ
Nucl Med Biol; 2014 Jul; 41(6):507-12. PubMed ID: 24768148
[TBL] [Abstract][Full Text] [Related]
7. Natural compound screening predicts novel GSK-3 isoform-specific inhibitors.
Ahmad F; Gupta A; Marzook H; Woodgett JR; Saleh MA; Qaisar R
Biochimie; 2024 May; 225():68-80. PubMed ID: 38723940
[TBL] [Abstract][Full Text] [Related]
8. Using topological indices to predict anti-Alzheimer and anti-parasitic GSK-3 inhibitors by multi-target QSAR in silico screening.
García I; Fall Y; Gómez G
Molecules; 2010 Aug; 15(8):5408-22. PubMed ID: 20714305
[TBL] [Abstract][Full Text] [Related]
9. Elucidation of the GSK3α Structure Informs the Design of Novel, Paralog-Selective Inhibitors.
Amaral B; Capacci A; Anderson T; Tezer C; Bajrami B; Lulla M; Lucas B; Chodaparambil JV; Marcotte D; Kumar PR; Murugan P; Spilker K; Cullivan M; Wang T; Peterson AC; Enyedy I; Ma B; Chen T; Yousaf Z; Calhoun M; Golonzhka O; Dillon GM; Koirala S
ACS Chem Neurosci; 2023 Mar; 14(6):1080-1094. PubMed ID: 36812145
[TBL] [Abstract][Full Text] [Related]
10. Glycogen synthesis and beyond, a comprehensive review of GSK3 as a key regulator of metabolic pathways and a therapeutic target for treating metabolic diseases.
Wang L; Li J; Di LJ
Med Res Rev; 2022 Mar; 42(2):946-982. PubMed ID: 34729791
[TBL] [Abstract][Full Text] [Related]
11. Advances of Zebrafish in Neurodegenerative Disease: From Models to Drug Discovery.
Wang X; Zhang JB; He KJ; Wang F; Liu CF
Front Pharmacol; 2021; 12():713963. PubMed ID: 34335276
[TBL] [Abstract][Full Text] [Related]
12. GSK3α: An Important Paralog in Neurodegenerative Disorders and Cancer.
Silva-García O; Cortés-Vieyra R; Mendoza-Ambrosio FN; Ramírez-Galicia G; Baizabal-Aguirre VM
Biomolecules; 2020 Dec; 10(12):. PubMed ID: 33339170
[TBL] [Abstract][Full Text] [Related]
13. Identification of a novel selective and potent inhibitor of glycogen synthase kinase-3.
Noori MS; Bhatt PM; Courreges MC; Ghazanfari D; Cuckler C; Orac CM; McMills MC; Schwartz FL; Deosarkar SP; Bergmeier SC; McCall KD; Goetz DJ
Am J Physiol Cell Physiol; 2019 Dec; 317(6):C1289-C1303. PubMed ID: 31553649
[TBL] [Abstract][Full Text] [Related]
14. Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia.
Wagner FF; Benajiba L; Campbell AJ; Weïwer M; Sacher JR; Gale JP; Ross L; Puissant A; Alexe G; Conway A; Back M; Pikman Y; Galinsky I; DeAngelo DJ; Stone RM; Kaya T; Shi X; Robers MB; Machleidt T; Wilkinson J; Hermine O; Kung A; Stein AJ; Lakshminarasimhan D; Hemann MT; Scolnick E; Zhang YL; Pan JQ; Stegmaier K; Holson EB
Sci Transl Med; 2018 Mar; 10(431):. PubMed ID: 29515000
[TBL] [Abstract][Full Text] [Related]
15. Docking and quantitative structure-activity relationship of oxadiazole derivates as inhibitors of GSK3β.
Quesada-Romero L; Caballero J
Mol Divers; 2014 Feb; 18(1):149-59. PubMed ID: 24081608
[TBL] [Abstract][Full Text] [Related]
16. Structure-based optimization of oxadiazole-based GSK-3 inhibitors.
Lo Monte F; Kramer T; Gu J; Brodrecht M; Pilakowski J; Fuertes A; Dominguez JM; Plotkin B; Eldar-Finkelman H; Schmidt B
Eur J Med Chem; 2013 Mar; 61():26-40. PubMed ID: 22749643
[TBL] [Abstract][Full Text] [Related]
17. Identification of glycogen synthase kinase-3 inhibitors with a selective sting for glycogen synthase kinase-3α.
Lo Monte F; Kramer T; Gu J; Anumala UR; Marinelli L; La Pietra V; Novellino E; Franco B; Demedts D; Van Leuven F; Fuertes A; Dominguez JM; Plotkin B; Eldar-Finkelman H; Schmidt B
J Med Chem; 2012 May; 55(9):4407-24. PubMed ID: 22533818
[TBL] [Abstract][Full Text] [Related]
18. Novel aryl and heteroaryl substituted N-[3-(4-phenylpiperazin-1-yl)propyl]-1,2,4-oxadiazole-5-carboxamides as selective GSK-3 inhibitors.
Koryakova AG; Ivanenkov YA; Ryzhova EA; Bulanova EA; Karapetian RN; Mikitas OV; Katrukha EA; Kazey VI; Okun I; Kravchenko DV; Lavrovsky YV; Korzinov OM; Ivachtchenko AV
Bioorg Med Chem Lett; 2008 Jun; 18(12):3661-6. PubMed ID: 18502121
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and structure-activity relationships of 1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3beta.
Saitoh M; Kunitomo J; Kimura E; Hayase Y; Kobayashi H; Uchiyama N; Kawamoto T; Tanaka T; Mol CD; Dougan DR; Textor GS; Snell GP; Itoh F
Bioorg Med Chem; 2009 Mar; 17(5):2017-29. PubMed ID: 19200745
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
